DUBLIN--(BUSINESS WIRE)--The "Oncology - Disease & Epidemiology Overview" report from Decision Resources Group has been added to ResearchAndMarkets.com's offering.
This report provides a disease market overview for each indication and global epidemiology overviews for each indication.
The Oncology Disease & Epidemiology Overview report provides disease market overviews and global epidemiology overviews for 32 indications in the Oncology therapy area:
Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myeloid Leukemia, Hodgkin's Lymphoma, Multiple Myeloma, Myelodysplastic Syndromes, Myelofibrosis, Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia, Antibody Drug Conjugates, Biomarkers in Oncology, Chimeric Antigen Receptor (CAR) T-Cell Therapy, Clinical Trial Design, High-Cost Hematological Malignancies, Immune Checkpoint Inhibitors, Oncology Clinical Trial Monitor, Supportive Care in Oncology, Therapeutic Vaccines and Viral Therapy, Bladder Cancer, Breast Cancer, Colorectal Cancer, Gastroesophageal Cancer, Glioma, Hepatocellular Carcinoma, Malignant Melanoma, Non-Small-Cell Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck and Thyroid Carcinoma Disease.
The disease market overviews include information such as market size forecasts, prevailing treatment trend analysis and predictions, key areas of unmet need, current and emerging therapies, physician (KOL) insights, clinical pipeline analysis, and more, for each indication.
The global epidemiology overviews provide insights including global diagnosed prevalence, diagnosed prevalence by region, 10-year diagnosed prevalence growth forecast, relative sizes of the factors contributing to the trend in prevalent cases, and more, for each indication.
Key Topics Covered:
- About the Analyst
- About the analyst's Epidemiology
- Disease Landscape and Insight Overview
- Epidemiology Overview
Companies Mentioned
- Merck & Co.
- Bristol Myers-Squibb
- Novartis
- Incyte
- CTI Biopharma
- Bioscience
For more information about this report visit https://www.researchandmarkets.com/research/8t474l/oncology_disease?w=4
